SlideShare ist ein Scribd-Unternehmen logo
1 von 29
Ebola Virus A to Z
Dr. Y. Ashok Babu
Contents of the topic:
• About the virus (taxonomy)
• History of Ebola of Viral Disease
• Geographical Distribution and Epidemiological preamble
• Molecular Biology of the Virus
• Host pathogen interaction (Entry, Replication and Host immunity
evasion)
• Patho-physiology and clinical manifestations
• Diagnosis
• Treatment and complications
• Disease out brake dynamics
• Management of Ebola outbreak at Health care facilities and
handling of the virus
•Threat perception for India
• Conclusion
• Ebola Virus is a ss(-)RNA Virus
• Belongs to order Mononegi virales, Family filovoviridae
• Current species in circulation causing major out breaks is Zaire
ebola virus
• The other virus species which cause Ebola virus disease
include
 Bundibugyo ebolavirus (BDBV)
 Reston ebolavirus (RESTV) –(Live Stock Infection)
 Sudan ebolavirus (SUDV)
 Taï Forest ebolavirus (TAFV) – Asia (Live stock Infection)
Marburg Virus is another genus of Filoviridae causing similar
hemaregic fever with comparative less fatality (30%)
History of Ebola Virus Disease
 Initially it was suspected as a species of Marburg Virus with
high virulence recent genetic analysis confirmed as new genus
with 70% homology to Marburg virus
 Since no treatment exists and symptoms are similar to
marburg virus the management of the disease followed same
procedure
 The first case of the infection reported in Zaire (1977) now
called DRC with case fatality of 88%.
 The spread of the disease attributed a single incidence of
handling carcasses dead baboons by a single human which
triggered human to human in close contacts.
Date Country Species
Reported
cases
Reported
deaths
Fatality
1976 Zaire ZEBOV 318 280 88%
1976 Sudan SEBOV 284 151 53%
1979 Sudan SEBOV 34 22 65%
1994 Gabon ZEBOV 52 31 60%
1995 Zaire ZEBOV 315 250 79%
1996 Jan–Apr Gabon ZEBOV 37 21 57%
1996–1997Jul–Jan Gabon ZEBOV 60 45 75%
2000–2001 Uganda SEBOV 425 224 53%
2001–2002 Oct–Jul
Gabon
Congo
ZEBOV 122 96 79%
2002–2003 Dec–Apr Congo ZEBOV 143 128 90%
2003 Nov–Dec Congo ZEBOV 35 29 83%
2007 DR Congo ZEBOV 264 187 71%
2007–2008 Dec–Jan Uganda BDBV 149 37 25%
2008–2009 Dec–Feb DR Congo ZEBOV 32 14 45%
2012 Jun–Aug Uganda SEBOV 24 17 71%
2012 Jun–Nov DR Congo BDBV 77 36 47%
2013–2014
Dec–present
Guinea, Liberia
Sierra Leone
Nigeria
ZEBOV 1848 1013 64%
Molecular Biology of the Virus
 The virus is a filamentus negative sense SS RNA virus with genome
size of 19kb
 The genome of Ebola virus is continues and codes for 7 structural
genes
 NP: Nucleoprotein…………….Nuclear capsid protein
 VP35: Virion Protein 35……. Polymerase complex
 VP 40: Virion Protein 40…… Matrix Protein
 Gp/sGP: Glyco Protein……….Trans membrane/secretory protein
 VP30: Virion Protein 30……..Transcription regulatory protein
 VP 24: Virion 24…………………. Matrix associated ??? .
 L: RNA dependent RNA polymerase
Schematic diagram showing a typical Ebola Virion
Host pathogen Interaction
The primary targets of Ebola virus is cell of lymphoid tissues including Dendritic
cells, Monocytes, and Epithelial cells.
However, after initiation of infection in the host the virus can infect all type cells
expressing NPC C1 protein.
The virus enters into the cytoplasm of host cell through Macropinocytosis.
Entry of the virus occurs in two phases, at both the phases involving interaction
of GP protein of the virus with host receptors.
Multiple targets for binding of GP protein on cell surfaced was found such as
Intigrins, Lectins, TAM
Virus internalizes into Macro Pinosome
GP1,2 protein cleaved by cathepsin B and L at the glycosylation
rich region GP1 exposing Receptor binding domine.
Receptor Binding site interact with NPC C1 on Macropinosome
leading to release of viral content into the cytoplasm
Being –ssRNA the virus carries along with it the RdRP (L-protein)
to initiate transcription.
The whole genome of the virus is under control of a single
promoter and ORF site at -1 of NP protein.
The peculiar feature of -ssRNA viruses is they have start and stop
regions at the beginning and end of each gene, leading to high
expression of proteins near to promoter than the gene located
away.
Entry of Ebola Virus into the cell
Over view of life cycle of Ebola virus
Host Immunity evasion
 The Ebola infection is fast acting, and highly replicating coupled
with disturbing host protein synthesis
 The virus rapid multiplication outperforms the cellular protection
mechanism leading initial failure of humeral immunity to contain
infection
 The virus releases a secretory form of GP out of the infected cell
in abundance which due to epitope cross reactivity to full GP
competes to bind with neutralizing anti bodies leading to failed
immune response.
 The same reason is the leading concern in developing vaccine
against Ebola infection.
Symptoms of Ebola Virus
Initial Signs
• Fever (at least 102°F)
• Weakness & exhaustion
• Pain
– Severe headache
– Muscles & joints
– Abdominal pain
• Sore throat
• Nausea
• Dizziness
Progressed Symptoms
• Vomiting
• Diarrhea
• Extensive bleeding
– Red eyes
• hemorrhage of sclerotic arterioles
– From mouth, nose, eyes, rectum &
mucouse membranes
• Maculopapular rash
– Spreads over the body (often
hemorrhagic)
• Other secondary symptoms
– Hypotension , Hypovolemia , Tachycardia
– Organ damage
– Internal and external bleeding
Diagnosis: Tool and Techniques
The clinical samples of Ebola virus infection pose serious Bio Hazard to laboratory
workers at par with the care givers.
Use of protocols involving possible generation of Aerosol such as pippetting,
Centrifugation, overtaxing completely banned outside BSL4 facility
Treatment and complications
There is no treatment for the infection of Ebola Virus.
Symptomatic supportive care can be given to the Individuals
including re hydration, supplementing with coagulation factors.
The virus pose high risk of Nosocomial transmission and hence
bio hazardous to health care workers and doctors.
Various studies on protection against EBOV infection in non
human primates with monoclonal antibodies, and si RNA
against NP and VP40 protein shown encouraging results.
There is no FDA approved therapy available for either Pre- or
Post exposure to the virus
However, very recently an American doctor and his assistant
who acquired the Infection was given the experimental drug
containing monoclonal antibodies against three EBOV.
Both of them recovered from the infection
On 6th August in the meeting of WHO it has recommended that
a controlled treatment with experimental drug may be
permitted in humans with learned consent as humanitarian
crisis over looming over ethics of experimental drug use.
However, the WHO recommendations limited to 2014 Ebola
outbreak only
Management of Ebola outbreak at Health care facilities
 Ebola vial infection is highly contagious with rapid health
deterioration in the infected patients
 The virus get secreted in abundance in all body fluids including
tears, saliva, blood, vomit, urine.
 Extreme personal protection is required while handling the
infected patients, and contaminated material.
 WHO, CDC recommended personal protection protocol after the
recent outbreak include full impermeable suite (Single use), N95
particulate filter max, impermeable boots, and gloves, protective
goggles.
 Minimum handling of the infected patient is recommended and
patient care by the relatives may be totally avoided except in case of
children with full protection
 Frequent hand hygiene with detergent or alcohol based solutions is
paramount to protect against infection in health care workers
 The virus can be easily get destroyed by 70% alcohol , 0.05% Sodium
Hypochlorite solution, bleaching powder or solution containing 500ppm
chlorine.
 Contaminated materials need to be treated with above solution before
disposal , if available incineration of contaminated materials such as
clothes, cotton swabs soiled with body fluids.
 Funeral of dead people with confirmed or suspected Ebola infection
should be strictly adhered to personal protection protocol, Un-protected
handling of dead body should be fully avoided
Threat perception for India
Ebola is a zoonotic infection transmitted through a direct or indirect
contact with the reservoir
Initial contact with natural reservoir fruit bat or in contact with infected
monkeys, other non human primates is the actual trigger for initiation of
spread of disease
Persistence of the disease in the wild depends on abundance of the
carrier in the area, and its initial spread largely depends on human and
wild animal contact
In Sub-Saharan region predominantly of worlds poorest countries,
majority of the population depend on forest, and consumption of wild
animals which make these population vulnerable to repeated epidemic
of the infection.
This single point shows how this virus remained an exotic pathogen to
India.
However, In the recent decades with increased economic interaction with
African countries, and presence of Indian UN peace keeping forces made
transmission of the disease to India become a possible threat
Heightened monitoring public transiting from these countries at entry points is
the most important to prevent entry of the virus.
With proper health care management in the event of out break the disease may
be contained. The extent of causality is inversely proportional to the availability
quality health care facilities.
Since the infection pose a serious Nosocomial bio-hazard, proper equipping
with PPE, training of health care workers and doctors should be initiated.
Mass awareness about the disease and spread of disease may be issued to
general public, which is sufficient at the moment.
With the reports of 4 Indian doctors want to return to India in fear of
Ebola infection where doctors health workers of WHO, MSF, Samaritan
Purse combating to contain the disease spread, there will requirement
of sensitization of Indian health care workers, and doctors for their
cooperation as the disease is a serious threat to health care givers.
Since entry point for the pathogen is major cities with international air
ports, Establishing quarantine facility is easier than other places as
such cities have better health care infra structure.
Conclusion
The ebola virus infection causes severe hemorrhagic disease with case
fatality ranging from 30% to 90% among different species.
The species causing the current out break is Zaire Ebola virus with high
case fatality rate of above 70%
Morphologically Ebola virus resembles with that of other filoviride
virus Marburg virus with a difference of filament size
With small molecule inhibitors NPC 1 (Cholesterol carrier) indentified
to be the required for entry of virus into cytoplasm
The viral protein GP shown to be cytotoxic to epithelial cells causing
inhibition of expression of cell adhesion molecules leading to vesicular
leakage.
Ebola virus evade host immunity by antibody subversion, by
producing antigen decoys, which render neutralizing antibodies
useless.
Early diagnosis of the infection involves Antigen Capture ELISA, PCR, RT-PCR,
IgM detection and electron microscopy, In the later stage of disease the
infection may be detected by IgG ELISA apart from above methods.
Treatment with monoclonal antibodies against the virus may be possible as
researchers shown their positive effect in mouse and no human primates.
Aseptic management and handling of infected persons and contaminated
materials is the key to containment of the disease.
Repeated outbreak of the Ebola virus is associated with regular human and
wild animal contact which is prevalent in African countries. Poor Health
care infrastructure fans the spread of disease from human to human.
Prevention of entry of the pathogen is paramount for India.
Thanks

Weitere ähnliche Inhalte

Was ist angesagt?

ebola-prevention and challenges
ebola-prevention and challengesebola-prevention and challenges
ebola-prevention and challengesChitra Pai
 
Ebola Experience in Sierra Leone Grand Rounds, May 2015 Marshfield Clinic
Ebola Experience in Sierra Leone Grand Rounds, May 2015 Marshfield ClinicEbola Experience in Sierra Leone Grand Rounds, May 2015 Marshfield Clinic
Ebola Experience in Sierra Leone Grand Rounds, May 2015 Marshfield ClinicVijay Aswani MD PhD FACP
 
Ebola What You Need To Know
Ebola What You Need To KnowEbola What You Need To Know
Ebola What You Need To KnowBarry Miskin
 
Ebola virus disease
Ebola virus diseaseEbola virus disease
Ebola virus diseaseMADHUR VERMA
 
Ebola virus disease by Aminu Arzet
Ebola virus disease by Aminu ArzetEbola virus disease by Aminu Arzet
Ebola virus disease by Aminu ArzetAminuArzet
 
Ebola Presentation
Ebola PresentationEbola Presentation
Ebola PresentationShanae Lee
 
Ebola virus disease
Ebola virus diseaseEbola virus disease
Ebola virus diseaseAlvin Chew
 
ebola-epidemiology
ebola-epidemiologyebola-epidemiology
ebola-epidemiologyChitra Pai
 
Ebola Virus Disease outbreak, 2014
Ebola Virus Disease outbreak, 2014Ebola Virus Disease outbreak, 2014
Ebola Virus Disease outbreak, 2014Tim Inglis
 
Ebola virus (Ebola Hemorrhagic Fever) by S Shivani Shastrulagari
Ebola virus (Ebola Hemorrhagic Fever) by S Shivani Shastrulagari Ebola virus (Ebola Hemorrhagic Fever) by S Shivani Shastrulagari
Ebola virus (Ebola Hemorrhagic Fever) by S Shivani Shastrulagari shivani shastrulagari
 
Ebola virus Disease Preparedness PGIMER DR RMLHospital New Delhi August 2014
Ebola virus Disease Preparedness PGIMER DR RMLHospital New Delhi August 2014Ebola virus Disease Preparedness PGIMER DR RMLHospital New Delhi August 2014
Ebola virus Disease Preparedness PGIMER DR RMLHospital New Delhi August 2014seema wasnik
 

Was ist angesagt? (20)

Ebola virus
Ebola virusEbola virus
Ebola virus
 
ebola-prevention and challenges
ebola-prevention and challengesebola-prevention and challenges
ebola-prevention and challenges
 
Ebola Experience in Sierra Leone Grand Rounds, May 2015 Marshfield Clinic
Ebola Experience in Sierra Leone Grand Rounds, May 2015 Marshfield ClinicEbola Experience in Sierra Leone Grand Rounds, May 2015 Marshfield Clinic
Ebola Experience in Sierra Leone Grand Rounds, May 2015 Marshfield Clinic
 
Ebola What You Need To Know
Ebola What You Need To KnowEbola What You Need To Know
Ebola What You Need To Know
 
Ebola virus disease
Ebola virus diseaseEbola virus disease
Ebola virus disease
 
Ebola
EbolaEbola
Ebola
 
Ebola virus disease
Ebola virus diseaseEbola virus disease
Ebola virus disease
 
Ebola Virus
Ebola VirusEbola Virus
Ebola Virus
 
Ebola virus
Ebola virusEbola virus
Ebola virus
 
Ebola virus
Ebola virusEbola virus
Ebola virus
 
Ebola virus disease by Aminu Arzet
Ebola virus disease by Aminu ArzetEbola virus disease by Aminu Arzet
Ebola virus disease by Aminu Arzet
 
Ebola Presentation
Ebola PresentationEbola Presentation
Ebola Presentation
 
Ebola ppt
Ebola pptEbola ppt
Ebola ppt
 
Ebola virus disease
Ebola virus diseaseEbola virus disease
Ebola virus disease
 
ebola-epidemiology
ebola-epidemiologyebola-epidemiology
ebola-epidemiology
 
Ebola virus
Ebola virusEbola virus
Ebola virus
 
Ebola Virus Disease outbreak, 2014
Ebola Virus Disease outbreak, 2014Ebola Virus Disease outbreak, 2014
Ebola Virus Disease outbreak, 2014
 
ebola virus
ebola virusebola virus
ebola virus
 
Ebola virus (Ebola Hemorrhagic Fever) by S Shivani Shastrulagari
Ebola virus (Ebola Hemorrhagic Fever) by S Shivani Shastrulagari Ebola virus (Ebola Hemorrhagic Fever) by S Shivani Shastrulagari
Ebola virus (Ebola Hemorrhagic Fever) by S Shivani Shastrulagari
 
Ebola virus Disease Preparedness PGIMER DR RMLHospital New Delhi August 2014
Ebola virus Disease Preparedness PGIMER DR RMLHospital New Delhi August 2014Ebola virus Disease Preparedness PGIMER DR RMLHospital New Delhi August 2014
Ebola virus Disease Preparedness PGIMER DR RMLHospital New Delhi August 2014
 

Andere mochten auch

Real Heroes - Tribute to Ebola Health Workers Who Risk Their Lives to Save Ot...
Real Heroes - Tribute to Ebola Health Workers Who Risk Their Lives to Save Ot...Real Heroes - Tribute to Ebola Health Workers Who Risk Their Lives to Save Ot...
Real Heroes - Tribute to Ebola Health Workers Who Risk Their Lives to Save Ot...Khawaja Umer Farooq Uddin
 
Asian indian phenotype
Asian indian phenotypeAsian indian phenotype
Asian indian phenotypeGuruprasad P
 
2014 Pictures of the year: Ebola
2014 Pictures of the year: Ebola2014 Pictures of the year: Ebola
2014 Pictures of the year: Ebolaguimera
 
Antinuclear Antibodies by Bio-Plex 2200
Antinuclear Antibodies by Bio-Plex 2200Antinuclear Antibodies by Bio-Plex 2200
Antinuclear Antibodies by Bio-Plex 2200Marta Talise
 
TIME’s 2014 Person of the Year
TIME’s 2014 Person of the Year TIME’s 2014 Person of the Year
TIME’s 2014 Person of the Year guimera
 
ANTINUCLEAR ANTIBODY
ANTINUCLEAR  ANTIBODYANTINUCLEAR  ANTIBODY
ANTINUCLEAR ANTIBODYMusa Khan
 
reactive arthritis
reactive arthritisreactive arthritis
reactive arthritistodam1
 
Ebola virus disease/ Ebola outbreak
Ebola virus disease/ Ebola outbreakEbola virus disease/ Ebola outbreak
Ebola virus disease/ Ebola outbreakRizwan S A
 
Taxonomy of plant viruses
Taxonomy of plant virusesTaxonomy of plant viruses
Taxonomy of plant virusesMaham Naveed
 
Immunofluorescence PPT
Immunofluorescence PPTImmunofluorescence PPT
Immunofluorescence PPTali7070
 
Ebola presentation
Ebola presentationEbola presentation
Ebola presentationJon Brown
 
Biological methods for nanoparticle synthesis
Biological methods for nanoparticle synthesisBiological methods for nanoparticle synthesis
Biological methods for nanoparticle synthesisVaibhav Maurya
 
Chapter 2 classification of virus
Chapter 2 classification of virusChapter 2 classification of virus
Chapter 2 classification of virusAlia Najiha
 

Andere mochten auch (20)

Real Heroes - Tribute to Ebola Health Workers Who Risk Their Lives to Save Ot...
Real Heroes - Tribute to Ebola Health Workers Who Risk Their Lives to Save Ot...Real Heroes - Tribute to Ebola Health Workers Who Risk Their Lives to Save Ot...
Real Heroes - Tribute to Ebola Health Workers Who Risk Their Lives to Save Ot...
 
Asian indian phenotype
Asian indian phenotypeAsian indian phenotype
Asian indian phenotype
 
Ebola
EbolaEbola
Ebola
 
2014 Pictures of the year: Ebola
2014 Pictures of the year: Ebola2014 Pictures of the year: Ebola
2014 Pictures of the year: Ebola
 
Ana
AnaAna
Ana
 
Antinuclear Antibodies by Bio-Plex 2200
Antinuclear Antibodies by Bio-Plex 2200Antinuclear Antibodies by Bio-Plex 2200
Antinuclear Antibodies by Bio-Plex 2200
 
anti nuclear antibody
anti nuclear antibodyanti nuclear antibody
anti nuclear antibody
 
TIME’s 2014 Person of the Year
TIME’s 2014 Person of the Year TIME’s 2014 Person of the Year
TIME’s 2014 Person of the Year
 
ANTINUCLEAR ANTIBODY
ANTINUCLEAR  ANTIBODYANTINUCLEAR  ANTIBODY
ANTINUCLEAR ANTIBODY
 
reactive arthritis
reactive arthritisreactive arthritis
reactive arthritis
 
Ebola virus disease/ Ebola outbreak
Ebola virus disease/ Ebola outbreakEbola virus disease/ Ebola outbreak
Ebola virus disease/ Ebola outbreak
 
Taxonomy of plant viruses
Taxonomy of plant virusesTaxonomy of plant viruses
Taxonomy of plant viruses
 
Reactive Arthritis
Reactive  ArthritisReactive  Arthritis
Reactive Arthritis
 
Ebola ppt
Ebola pptEbola ppt
Ebola ppt
 
Immunofluorescence PPT
Immunofluorescence PPTImmunofluorescence PPT
Immunofluorescence PPT
 
Ebola presentation
Ebola presentationEbola presentation
Ebola presentation
 
Virus powerpoint
Virus powerpointVirus powerpoint
Virus powerpoint
 
Plant virus
Plant virusPlant virus
Plant virus
 
Biological methods for nanoparticle synthesis
Biological methods for nanoparticle synthesisBiological methods for nanoparticle synthesis
Biological methods for nanoparticle synthesis
 
Chapter 2 classification of virus
Chapter 2 classification of virusChapter 2 classification of virus
Chapter 2 classification of virus
 

Ähnlich wie Ebola Virus A to Z Guide

EBOLA VIRUS DISEASE.pptx
EBOLA VIRUS DISEASE.pptxEBOLA VIRUS DISEASE.pptx
EBOLA VIRUS DISEASE.pptxRohan Sahoo
 
Ebola Outbreak in Liberia : August 2014
Ebola Outbreak in Liberia : August 2014Ebola Outbreak in Liberia : August 2014
Ebola Outbreak in Liberia : August 2014Amit Bhagat
 
Ebola virus disease - A comprehensive review
Ebola virus disease - A comprehensive reviewEbola virus disease - A comprehensive review
Ebola virus disease - A comprehensive reviewpharmaindexing
 
Ebola virus complete ppt students of jcpt -m.b
Ebola virus complete ppt students of jcpt -m.bEbola virus complete ppt students of jcpt -m.b
Ebola virus complete ppt students of jcpt -m.bBHASKAR43
 
Ebola Virus ,HAEMORRHAGIC FEVER
Ebola Virus ,HAEMORRHAGIC FEVEREbola Virus ,HAEMORRHAGIC FEVER
Ebola Virus ,HAEMORRHAGIC FEVERHeena Parveen
 
Ebola biology investigatory project
Ebola biology investigatory projectEbola biology investigatory project
Ebola biology investigatory projectShilpi Srivastava
 
Fighting Against Ebola: Public Health and Nepal
Fighting Against Ebola: Public Health and NepalFighting Against Ebola: Public Health and Nepal
Fighting Against Ebola: Public Health and NepalMMC, IOM, Nepal
 
Ebola virus disease [ bio project ]
Ebola virus disease [ bio project ] Ebola virus disease [ bio project ]
Ebola virus disease [ bio project ] Abhishek Nayak
 
EBOLA & OTHER VHF 2022.pptx
EBOLA & OTHER VHF 2022.pptxEBOLA & OTHER VHF 2022.pptx
EBOLA & OTHER VHF 2022.pptxMkindi Mkindi
 
Ebola Hemorrhagic Fever pptx
Ebola Hemorrhagic Fever pptxEbola Hemorrhagic Fever pptx
Ebola Hemorrhagic Fever pptxSHAFIIMOHAMED1
 
Preventive medicine cholera, sars, ebola virus
Preventive medicine cholera, sars, ebola virusPreventive medicine cholera, sars, ebola virus
Preventive medicine cholera, sars, ebola virusAshish Chaudhari
 

Ähnlich wie Ebola Virus A to Z Guide (20)

EBOLA VIRUS DISEASE.pptx
EBOLA VIRUS DISEASE.pptxEBOLA VIRUS DISEASE.pptx
EBOLA VIRUS DISEASE.pptx
 
Ebola Outbreak in Liberia : August 2014
Ebola Outbreak in Liberia : August 2014Ebola Outbreak in Liberia : August 2014
Ebola Outbreak in Liberia : August 2014
 
Ebola virus disease - A comprehensive review
Ebola virus disease - A comprehensive reviewEbola virus disease - A comprehensive review
Ebola virus disease - A comprehensive review
 
Ebola virus complete ppt students of jcpt -m.b
Ebola virus complete ppt students of jcpt -m.bEbola virus complete ppt students of jcpt -m.b
Ebola virus complete ppt students of jcpt -m.b
 
Ebola virus
Ebola virusEbola virus
Ebola virus
 
EBOLA VIRUS
EBOLA VIRUSEBOLA VIRUS
EBOLA VIRUS
 
Ebola
EbolaEbola
Ebola
 
Ebola Virus ,HAEMORRHAGIC FEVER
Ebola Virus ,HAEMORRHAGIC FEVEREbola Virus ,HAEMORRHAGIC FEVER
Ebola Virus ,HAEMORRHAGIC FEVER
 
Ebola viruses
Ebola virusesEbola viruses
Ebola viruses
 
Ebola biology investigatory project
Ebola biology investigatory projectEbola biology investigatory project
Ebola biology investigatory project
 
What is ebola
What is ebolaWhat is ebola
What is ebola
 
Fighting Against Ebola: Public Health and Nepal
Fighting Against Ebola: Public Health and NepalFighting Against Ebola: Public Health and Nepal
Fighting Against Ebola: Public Health and Nepal
 
Ebola virus disease [ bio project ]
Ebola virus disease [ bio project ] Ebola virus disease [ bio project ]
Ebola virus disease [ bio project ]
 
EBOLA & OTHER VHF 2022.pptx
EBOLA & OTHER VHF 2022.pptxEBOLA & OTHER VHF 2022.pptx
EBOLA & OTHER VHF 2022.pptx
 
Ebola Virus
Ebola Virus Ebola Virus
Ebola Virus
 
Ebola
EbolaEbola
Ebola
 
Ebola Viruspptx
Ebola ViruspptxEbola Viruspptx
Ebola Viruspptx
 
Ebola Hemorrhagic Fever pptx
Ebola Hemorrhagic Fever pptxEbola Hemorrhagic Fever pptx
Ebola Hemorrhagic Fever pptx
 
Preventive medicine cholera, sars, ebola virus
Preventive medicine cholera, sars, ebola virusPreventive medicine cholera, sars, ebola virus
Preventive medicine cholera, sars, ebola virus
 
Ebola virus
Ebola virusEbola virus
Ebola virus
 

Kürzlich hochgeladen

Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformKweku Zurek
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...saminamagar
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxDr.Nusrat Tariq
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...saminamagar
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?bkling
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 

Kürzlich hochgeladen (20)

Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptx
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
 
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
call girls in Dwarka Sector 21 Metro DELHI 🔝 >༒9540349809 🔝 genuine Escort Se...
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in aerocity DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 

Ebola Virus A to Z Guide

  • 1. Ebola Virus A to Z Dr. Y. Ashok Babu
  • 2. Contents of the topic: • About the virus (taxonomy) • History of Ebola of Viral Disease • Geographical Distribution and Epidemiological preamble • Molecular Biology of the Virus • Host pathogen interaction (Entry, Replication and Host immunity evasion) • Patho-physiology and clinical manifestations • Diagnosis • Treatment and complications • Disease out brake dynamics • Management of Ebola outbreak at Health care facilities and handling of the virus •Threat perception for India • Conclusion
  • 3. • Ebola Virus is a ss(-)RNA Virus • Belongs to order Mononegi virales, Family filovoviridae • Current species in circulation causing major out breaks is Zaire ebola virus • The other virus species which cause Ebola virus disease include  Bundibugyo ebolavirus (BDBV)  Reston ebolavirus (RESTV) –(Live Stock Infection)  Sudan ebolavirus (SUDV)  Taï Forest ebolavirus (TAFV) – Asia (Live stock Infection) Marburg Virus is another genus of Filoviridae causing similar hemaregic fever with comparative less fatality (30%)
  • 4. History of Ebola Virus Disease  Initially it was suspected as a species of Marburg Virus with high virulence recent genetic analysis confirmed as new genus with 70% homology to Marburg virus  Since no treatment exists and symptoms are similar to marburg virus the management of the disease followed same procedure  The first case of the infection reported in Zaire (1977) now called DRC with case fatality of 88%.  The spread of the disease attributed a single incidence of handling carcasses dead baboons by a single human which triggered human to human in close contacts.
  • 5. Date Country Species Reported cases Reported deaths Fatality 1976 Zaire ZEBOV 318 280 88% 1976 Sudan SEBOV 284 151 53% 1979 Sudan SEBOV 34 22 65% 1994 Gabon ZEBOV 52 31 60% 1995 Zaire ZEBOV 315 250 79% 1996 Jan–Apr Gabon ZEBOV 37 21 57% 1996–1997Jul–Jan Gabon ZEBOV 60 45 75% 2000–2001 Uganda SEBOV 425 224 53% 2001–2002 Oct–Jul Gabon Congo ZEBOV 122 96 79% 2002–2003 Dec–Apr Congo ZEBOV 143 128 90% 2003 Nov–Dec Congo ZEBOV 35 29 83% 2007 DR Congo ZEBOV 264 187 71% 2007–2008 Dec–Jan Uganda BDBV 149 37 25% 2008–2009 Dec–Feb DR Congo ZEBOV 32 14 45% 2012 Jun–Aug Uganda SEBOV 24 17 71% 2012 Jun–Nov DR Congo BDBV 77 36 47% 2013–2014 Dec–present Guinea, Liberia Sierra Leone Nigeria ZEBOV 1848 1013 64%
  • 6.
  • 7. Molecular Biology of the Virus  The virus is a filamentus negative sense SS RNA virus with genome size of 19kb  The genome of Ebola virus is continues and codes for 7 structural genes  NP: Nucleoprotein…………….Nuclear capsid protein  VP35: Virion Protein 35……. Polymerase complex  VP 40: Virion Protein 40…… Matrix Protein  Gp/sGP: Glyco Protein……….Trans membrane/secretory protein  VP30: Virion Protein 30……..Transcription regulatory protein  VP 24: Virion 24…………………. Matrix associated ??? .  L: RNA dependent RNA polymerase
  • 8. Schematic diagram showing a typical Ebola Virion
  • 9.
  • 10. Host pathogen Interaction The primary targets of Ebola virus is cell of lymphoid tissues including Dendritic cells, Monocytes, and Epithelial cells. However, after initiation of infection in the host the virus can infect all type cells expressing NPC C1 protein. The virus enters into the cytoplasm of host cell through Macropinocytosis. Entry of the virus occurs in two phases, at both the phases involving interaction of GP protein of the virus with host receptors. Multiple targets for binding of GP protein on cell surfaced was found such as Intigrins, Lectins, TAM Virus internalizes into Macro Pinosome
  • 11. GP1,2 protein cleaved by cathepsin B and L at the glycosylation rich region GP1 exposing Receptor binding domine. Receptor Binding site interact with NPC C1 on Macropinosome leading to release of viral content into the cytoplasm Being –ssRNA the virus carries along with it the RdRP (L-protein) to initiate transcription. The whole genome of the virus is under control of a single promoter and ORF site at -1 of NP protein. The peculiar feature of -ssRNA viruses is they have start and stop regions at the beginning and end of each gene, leading to high expression of proteins near to promoter than the gene located away.
  • 12. Entry of Ebola Virus into the cell
  • 13. Over view of life cycle of Ebola virus
  • 14. Host Immunity evasion  The Ebola infection is fast acting, and highly replicating coupled with disturbing host protein synthesis  The virus rapid multiplication outperforms the cellular protection mechanism leading initial failure of humeral immunity to contain infection  The virus releases a secretory form of GP out of the infected cell in abundance which due to epitope cross reactivity to full GP competes to bind with neutralizing anti bodies leading to failed immune response.  The same reason is the leading concern in developing vaccine against Ebola infection.
  • 15.
  • 16. Symptoms of Ebola Virus Initial Signs • Fever (at least 102°F) • Weakness & exhaustion • Pain – Severe headache – Muscles & joints – Abdominal pain • Sore throat • Nausea • Dizziness Progressed Symptoms • Vomiting • Diarrhea • Extensive bleeding – Red eyes • hemorrhage of sclerotic arterioles – From mouth, nose, eyes, rectum & mucouse membranes • Maculopapular rash – Spreads over the body (often hemorrhagic) • Other secondary symptoms – Hypotension , Hypovolemia , Tachycardia – Organ damage – Internal and external bleeding
  • 17.
  • 18. Diagnosis: Tool and Techniques The clinical samples of Ebola virus infection pose serious Bio Hazard to laboratory workers at par with the care givers. Use of protocols involving possible generation of Aerosol such as pippetting, Centrifugation, overtaxing completely banned outside BSL4 facility
  • 19.
  • 20. Treatment and complications There is no treatment for the infection of Ebola Virus. Symptomatic supportive care can be given to the Individuals including re hydration, supplementing with coagulation factors. The virus pose high risk of Nosocomial transmission and hence bio hazardous to health care workers and doctors. Various studies on protection against EBOV infection in non human primates with monoclonal antibodies, and si RNA against NP and VP40 protein shown encouraging results. There is no FDA approved therapy available for either Pre- or Post exposure to the virus
  • 21. However, very recently an American doctor and his assistant who acquired the Infection was given the experimental drug containing monoclonal antibodies against three EBOV. Both of them recovered from the infection On 6th August in the meeting of WHO it has recommended that a controlled treatment with experimental drug may be permitted in humans with learned consent as humanitarian crisis over looming over ethics of experimental drug use. However, the WHO recommendations limited to 2014 Ebola outbreak only
  • 22. Management of Ebola outbreak at Health care facilities  Ebola vial infection is highly contagious with rapid health deterioration in the infected patients  The virus get secreted in abundance in all body fluids including tears, saliva, blood, vomit, urine.  Extreme personal protection is required while handling the infected patients, and contaminated material.  WHO, CDC recommended personal protection protocol after the recent outbreak include full impermeable suite (Single use), N95 particulate filter max, impermeable boots, and gloves, protective goggles.  Minimum handling of the infected patient is recommended and patient care by the relatives may be totally avoided except in case of children with full protection
  • 23.  Frequent hand hygiene with detergent or alcohol based solutions is paramount to protect against infection in health care workers  The virus can be easily get destroyed by 70% alcohol , 0.05% Sodium Hypochlorite solution, bleaching powder or solution containing 500ppm chlorine.  Contaminated materials need to be treated with above solution before disposal , if available incineration of contaminated materials such as clothes, cotton swabs soiled with body fluids.  Funeral of dead people with confirmed or suspected Ebola infection should be strictly adhered to personal protection protocol, Un-protected handling of dead body should be fully avoided
  • 24. Threat perception for India Ebola is a zoonotic infection transmitted through a direct or indirect contact with the reservoir Initial contact with natural reservoir fruit bat or in contact with infected monkeys, other non human primates is the actual trigger for initiation of spread of disease Persistence of the disease in the wild depends on abundance of the carrier in the area, and its initial spread largely depends on human and wild animal contact In Sub-Saharan region predominantly of worlds poorest countries, majority of the population depend on forest, and consumption of wild animals which make these population vulnerable to repeated epidemic of the infection. This single point shows how this virus remained an exotic pathogen to India.
  • 25. However, In the recent decades with increased economic interaction with African countries, and presence of Indian UN peace keeping forces made transmission of the disease to India become a possible threat Heightened monitoring public transiting from these countries at entry points is the most important to prevent entry of the virus. With proper health care management in the event of out break the disease may be contained. The extent of causality is inversely proportional to the availability quality health care facilities. Since the infection pose a serious Nosocomial bio-hazard, proper equipping with PPE, training of health care workers and doctors should be initiated. Mass awareness about the disease and spread of disease may be issued to general public, which is sufficient at the moment.
  • 26. With the reports of 4 Indian doctors want to return to India in fear of Ebola infection where doctors health workers of WHO, MSF, Samaritan Purse combating to contain the disease spread, there will requirement of sensitization of Indian health care workers, and doctors for their cooperation as the disease is a serious threat to health care givers. Since entry point for the pathogen is major cities with international air ports, Establishing quarantine facility is easier than other places as such cities have better health care infra structure.
  • 27. Conclusion The ebola virus infection causes severe hemorrhagic disease with case fatality ranging from 30% to 90% among different species. The species causing the current out break is Zaire Ebola virus with high case fatality rate of above 70% Morphologically Ebola virus resembles with that of other filoviride virus Marburg virus with a difference of filament size With small molecule inhibitors NPC 1 (Cholesterol carrier) indentified to be the required for entry of virus into cytoplasm The viral protein GP shown to be cytotoxic to epithelial cells causing inhibition of expression of cell adhesion molecules leading to vesicular leakage. Ebola virus evade host immunity by antibody subversion, by producing antigen decoys, which render neutralizing antibodies useless.
  • 28. Early diagnosis of the infection involves Antigen Capture ELISA, PCR, RT-PCR, IgM detection and electron microscopy, In the later stage of disease the infection may be detected by IgG ELISA apart from above methods. Treatment with monoclonal antibodies against the virus may be possible as researchers shown their positive effect in mouse and no human primates. Aseptic management and handling of infected persons and contaminated materials is the key to containment of the disease. Repeated outbreak of the Ebola virus is associated with regular human and wild animal contact which is prevalent in African countries. Poor Health care infrastructure fans the spread of disease from human to human. Prevention of entry of the pathogen is paramount for India.

Hinweis der Redaktion

  1. Ebola Virus A to Z
  2. Ebola Virus is a ss(-)RNA Virus
  3. History of Ebola Virus Disease
  4. The primary targets of Ebola virus is cell of lymphoid tissues including dendritic cells, monocytes, and epithelial cells
  5. However, very recently an American doctor and his assistant who acquired the Infection was given the experimental drug containing monoclonal antibodies against three EBOV.
  6. Ebola vial infection is highly contagious with rapid health deterioration in the infected patients
  7. Ho
  8. Thanks